Hansoh Pharmaceutical Group Company Limited announced that "HS-20106 Injections" (the "Product"), a Category 1 therapeutic biological product has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China. The specific indication will be determined after the completion of clinical research.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.22 HKD | +2.50% | +11.96% | +9.26% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.26% | 13.03B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 3692 Stock
- News Hansoh Pharmaceutical Group Company Limited
- Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections